Biweekly Chemo Duo Shows Promise for Pancreatic Cancer Patients Over 75
A prospective Phase II trial in Japan found that biweekly gemcitabine plus nab-paclitaxel produced a 47.1 percent response rate and ...
A prospective Phase II trial in Japan found that biweekly gemcitabine plus nab-paclitaxel produced a 47.1 percent response rate and ...
A large longitudinal study of Chinese adults finds that persistent handgrip strength asymmetry and any abnormal two-wave pattern of low ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine